Landmark TOPaZ Trial Finds Bone Density Drugs Do Not Prevent Fractures in Brittle Bone Disease
核心洞察
The TOPaZ trial followed 350 adults with osteogenesis imperfecta (搜索) over eight years and found bone density–increasing drugs did not reduce fracture risk compared to standard care.
Fracture rates were nearly identical: 37% in the treatment group versus 36% in the standard care group, challenging decades of clinical practice.
Experts now call for a shift toward therapies that improve bone quality by targeting collagen defects rather than simply increasing bone density.
A landmark clinical trial has upended decades of conventional wisdom in the treatment of brittle bone disease, demonstrating that medications designed to increase bone density do not reduce fracture risk in patients with osteogenesis imperfecta (搜索) (OI). The findings, published in JAMA, are expected to fundamentally reshape clinical practice for this rare genetic condition.
The TOPaZ trial, led by scientists at the University of Edinburgh, followed 350 adults with OI over eight years, from May 2017 to March 2025, across 27 hospitals in the UK and Europe. Half of the participants received drug treatments aimed at boosting bone density, while the other half received standard care. Despite significantly increased bone density in the treatment group, fracture outcomes were virtually identical: 37% of those receiving bone density treatment experienced fractures, compared with 36% of those receiving standard care.
"These findings challenge the long-held belief that better bone density could help those with the condition and suggest treatment strategies should instead focus on improving bone quality," the research team concluded.
A paradigm built on assumption
Osteogenesis imperfecta (搜索), which affects approximately 1 in every 15,000 people, is caused by a defect in collagen production—a protein essential for bone structure—leading to weak, fragile bones that can break with little or no trauma. For decades, clinicians have prescribed bone density–increasing drugs to these patients, extrapolating from osteoporosis treatment paradigms despite a lack of direct evidence that this approach reduces fractures in OI.
Stuart Ralston, study lead and Professor at the Institute of Genetics and Cancer, University of Edinburgh, stated: "We have been using drugs to increase bone density for decades in the hope that they might prevent fractures but the TOPaZ trial clearly shows that these medicines simply do not work. We now need to focus efforts on finding new drugs that can target the defects in bone collagen to improve the strength of bone and reduce fracture risk in this rare but serious disease."
The trial, supported by the Brittle Bone Society (搜索) and funded by the Medical Research Council and National Institute for Health and Care Research (搜索), represents the largest group of adults with OI studied to date.
Implications for future research and care
Patricia Osborne, CEO of the Brittle Bone Society (搜索), emphasized the significance of the findings for both patients and clinicians: "The results have given patients and clinicians clear evidence to guide treatment decisions and highlight the importance of OI-specific research. This study also shows the vital role that charity-supported research plays in challenging assumptions and ensuring people with OI receive care based on robust evidence."
Osborne added that the TOPaZ trial "sets a new benchmark and will directly influence how future trials are designed and delivered."
The results underscore a critical distinction between bone density and bone quality—a concept that may have broader implications beyond OI. While bone density remains a useful surrogate endpoint in osteoporosis, the TOPaZ findings demonstrate that in conditions where the fundamental bone matrix is defective, density alone is an insufficient therapeutic target.
A broader context in bone health
The TOPaZ results arrive amid ongoing debate about osteoporosis treatment strategies. In a recent JAMA Network opinion piece, Susan Ott, MD, of the University of Washington noted that the FDA recently changed requirements for approval of new osteoporosis medications from a patient-centered endpoint of clinical fracture to the surrogate endpoint of bone density. Ott cautioned that while bone density correlates with fracture risk in some contexts, the relationship is not universal—citing the historical example of fluoride, which increased spine bone density more than any other drug but was associated with a higher incidence of clinical fractures compared with placebo.
The TOPaZ trial now provides prospective, controlled evidence that increasing bone density does not necessarily translate to fracture prevention, at least in the context of collagen-based bone disorders. The findings point toward an urgent need for therapies that address the underlying molecular pathology of OI rather than borrowing strategies from osteoporosis care.